Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Drug

FDA Clears Elevidys Gene Therapy After Investigating 8-Year-Old Boy’s Death

Fineline Cube Aug 4, 2025

The U.S. Food and Drug Administration (FDA) has completed its investigation into the death of...

Company Drug

Mabwell’s CDH17-Targeted ADC 7MW4911 Receives Clinical Trial Approval in China and IND Clearance in the US

Fineline Cube Aug 4, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that its self-developed CDH17-targeted antibody-drug conjugate...

Company Drug

Cutia Therapeutics’ CU-40102 Approved in Hong Kong for Androgenetic Alopecia Treatment

Fineline Cube Aug 4, 2025

China-based dermatology specialist Cutia Therapeutics (HKG: 2487) announced today that its CU-40102 (finasteride topical spray)...

Company Drug

UTC Therapeutics Gains FDA Clearance for CAR-T Therapy UCLM805 in MSLN-Positive Solid Tumors

Fineline Cube Aug 4, 2025

China-based cell therapy biotech UTC Therapeutics announced receiving clearance from the US Food and Drug...

Company Drug Policy / Regulatory

FDA Mandates Safety Labeling Changes for Opioid Pain Medications and Targets 7-OH Products

Fineline Cube Aug 4, 2025

The U.S. Food and Drug Administration (FDA) is implementing new safety measures for opioid pain...

Company Drug

Luye Pharma’s LY03021 Completes Enrollment of First Healthy Subject in Phase I Trial

Fineline Cube Aug 4, 2025

China-based Luye Pharma Group (HKG: 2186) announced on August 3, 2025, that its self-developed Class...

Company Deals

AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis

Fineline Cube Aug 1, 2025

China-based AllianThera Biopharma (ATB) announced a strategic partnership with Germany’s Dr. Falk Pharma GmbH to...

Company Deals

Grand Pharma Partners with IRE EliT to Distribute 68Ge/68Ga Generators in China

Fineline Cube Aug 1, 2025

On July 31, 2025, China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced a strategic collaboration...

Company Drug

Lee’s Pharma’s Socazolimab Approved by NMPA for ES-SCLC First-Line Treatment

Fineline Cube Aug 1, 2025

Lee’s Pharmaceutical Holdings Ltd. (HKG: 0950) announced that its in-licensed programmed-death ligand 1 (PD-L1) monoclonal...

Company Deals

BrightGene and CR Sanjiu Collaborate on BGM0504 Injection Development and Commercialization

Fineline Cube Aug 1, 2025

China-based BrightGene Bio-Medical Technology Co., Ltd. (SHA: 688166) and its affiliated companies announced a collaboration...

Company

AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth

Fineline Cube Aug 1, 2025

US-based multinational AbbVie Inc. (NYSE: ABBV) reported strong Q2 2025 results with global revenues increasing...

Company

BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook

Fineline Cube Aug 1, 2025

US major Bristol-Myers Squibb (BMS; NYSE: BMY) reported Q2 2025 financial results, revealing total revenues...

Policy / Regulatory

China’s NHSA Issues Rules for Instant Settlement of Medical Insurance Funds

Fineline Cube Aug 1, 2025

China’s National Healthcare Security Administration (NHSA) has issued the “Interim Administrative Rules for Instant Settlement...

Company Deals

Hybio and BrightGene Partner on Peptide Raw Material Supply for Global Drug Commercialization

Fineline Cube Aug 1, 2025

China-based Hybio Pharmaceutical Co., Ltd. (SHE: 300199) and China-based BrightGene Bio-Medical Technology Co., Ltd. (SHA:...

Company Drug

BeOne Medicines’ BGB-16673 Granted PRIME Designation by EMA for Waldenström’s Macroglobulinemia

Fineline Cube Aug 1, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced on July 31, 2025,...

Company Drug

Neurodawn’s Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection

Fineline Cube Aug 1, 2025

China-based Neurodawn Pharmaceutical Co., Ltd.’s wholly-owned subsidiary, Fuzhou Ningdan Rongkang Biomedical Technology Co., Ltd. (Ningdan...

Policy / Regulatory

NMPA Seeks Public Feedback on Draft Regulations for Internet Drug and Medical Device Information Services

Fineline Cube Aug 1, 2025

On July 31, 2025, China’s National Medical Products Administration (NMPA) commenced soliciting public comments on...

Company Drug

Haisco’s Ciprofol NDA Accepted by FDA: A Milestone for Chinese Anesthesia Innovation

Fineline Cube Aug 1, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that the New Drug Application (NDA)...

Company Drug

AstraZeneca’s Ultomiris Gains NMPA Approval for Neuromyelitis Optica Spectrum Disorder

Fineline Cube Aug 1, 2025

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Chipscreen’s Next-Gen Brain-Penetrant Aurora B Inhibitor CS231295 Gains FDA Clearance for Advanced Solid Tumors

Fineline Cube Aug 1, 2025

On July 31, 2025, the investigational new drug (IND) application for Shenzhen Chipscreen Biosciences Co.,...

Posts pagination

1 … 173 174 175 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.